Biotech · Private company · San Diego, CA, US
Myogene Bio, LLC
Track this companyFree. Adds Myogene Bio, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards7
- Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophyFiscal year 2026 · $978.4KNIH RePORTER 5R44NS141438-05 · fetched Nov 12, 2026
- Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophyFiscal year 2026 · $498.4KNIH RePORTER 5SB1AR084953-02 · fetched Nov 12, 2026
- Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophyFiscal year 2025 · $302.5KNIH RePORTER 1R21HD117763-01 · fetched Nov 12, 2026
- Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophyFiscal year 2025 · $499.3KNIH RePORTER 1SB1AR084953-01A1 · fetched Nov 12, 2026
- Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophyFiscal year 2025 · $201.3KNIH RePORTER 5R21TR005162-02 · fetched Nov 12, 2026
- Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophyFiscal year 2025 · $1.3MNIH RePORTER 9R44NS141438-04 · fetched Nov 12, 2026
- Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophyFiscal year 2024 · $110KNIH RePORTER 1R21TR005162-01 · fetched Nov 12, 2026